Intraperitoneal Chemotherapy
NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreExtensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
Annals of Surgical Oncology 2022 December 10 [Link] Lukas F Liesenfeld, Eva Quiring, Mohammed Al-Saeedi, Christian Nusshag, Markus W Büchler, Martin Schneider Abstract Background: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity,…
Read MoreConditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative
Annals of Surgical Oncology 2022 October 30 [Link] Eliza W Beal, Shruthi Srinivas, Chengli Shen, Alex Kim, Fabian M Johnston, Jonathan Greer, Daniel E Abbott, Courtney Pokrzywa, Mustafa Raoof, Travis E Grotz, Jennifer L Leiting, Keith Fournier, Sean Dineen, Benjamin Powers, Jula Veerapong, Anai Kothari, Ugwuji Maduekew, Shishir Maithel, Gregory C Wilson, Sameer H Patel,…
Read MoreDesmoid-type fibromatosis in the setting of malignant peritoneal mesothelioma: a case report of two rare diseases
World Journal of Surgical Oncology 2022 September 28 [Link] Stephanie N Gregory, Audra A Satterwhite, H Richard Alexander, Andrew M Blakely Abstract Background: Desmoid-type fibromatosis (DTF) is a rare benign lesion that usually arises from the abdominal wall or extremities and rarely from the mesentery or intrabdominal organs. Malignant peritoneal mesothelioma is also a rare,…
Read MoreComprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin
Cancers 2022 September 1 [Link] Michel Adamina, Maxime Warlaumont, Martin D Berger, Silvio Däster, Raphaël Delaloye, Antonia Digklia, Beat Gloor, Ralph Fritsch, Dieter Koeberle, Thibaud Koessler, Kuno Lehmann, Phaedra Müller, Ralph Peterli, Frédéric Ris, Thomas Steffen, Christian Stefan Weisshaupt, Martin Hübner Abstract Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival…
Read MoreSubstance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study
International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…
Read MoreIntraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO
BMJ Open 2022 June 22 [Link] Job P van Kooten, Michelle V Dietz, Niels A D Guchelaar, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Jacobus W A Burger, Ron H J Mathijssen, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour…
Read MoreTen-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Langenbeck’s Archives of Surgery 2022 June 23 [Link] Miklos Acs, Michael Gerken, Ivana Gajic, Max Mayr, Jozef Zustin, Pompiliu Piso Abstract Purpose: This single-center study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (DMPM). Methods: Prospectively collected data from a single institution data registry was retrospectively investigated. Eighty-four…
Read MoreCytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre
Anticancer Research 2022 June [Link] Raphael Shamavonian, Ernest Cheng, Josh B Karpes, Shoma Barat, Nima Ahmadi, David L Morris Abstract Background/aim: The aim of the study was to determine outcomes and overall survival (OS) in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for malignant peritoneal mesothelioma (MPM). Patients and methods: This was…
Read MoreA Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies
Canadian Journal of Surgery 2022 May 17 [Link] Rami Nassabein, Rami Younan, Rasmy Loungarath, Frederic Mercier, Francois Dagbert, Francine Aubin, Jean Pierre Ayoub, Mustapha Tehfé Abstract Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is…
Read More